Market Overview

Investigation Report on Chinese Pregabalin Market, 2018-2022 -


The "Investigation
Report on Chinese Pregabalin Market, 2018-2022"
report has been
added to's offering.

Pregabalin is a new-generation drug for neuralgia treatment. In Jul.
2004, it was approved by the European Union to treat some epileptic
seizures in adults. In Dec. 2004, it was approved by the U.S. Food and
Drug Administration (FDA) to treat diabetic peripheral neuralgia and
postherpetic neuralgia. In 2006, generalized anxiety disorder and social
anxiety disorder became new indications of Pregabalin. In 2007,
Pregabalin was approved by the FDA as the first drug to treat
fibromyalgia syndrome. In 2012, Pregabalin was approved by the FDA to
treat spinal cord injury (SCI)-related pains. In 2010, Lyrica was
approved to enter China.

According to the research, the sales value of Lyrica increased by more
than 200 times from about CNY 200,000 in 2010 to over 40 million in
2017. Due to Lyrica's success, many domestic manufacturers applied for
Pregabalin production. Chongqing Succeway Pharmaceutical Co., Ltd.'s
Pregabalin (trade name: Lairuike) was put in the market after obtaining
the production license in 2013 and is gradually taking market share from
Pfizer. By sales value, in 2017, Pfizer's Lyrica had a market share of
approximately 79.8%, and the rest market share was captured by the
products of Chongqing Succeway Pharmaceutical Co., Ltd. It is estimated
that Pfizer's Lyrica will continue to dominate the Chinese market from
2018 to 2022 but its market share will decline because of the price
competition of China-made Pregabalin.

There is a continuous rise in the number of people suffering from
indications for Pregabalin. For example, the number of epileptics in
China has exceeded 10 million and increases by 400,000 every year.
Therefore, Pregabalin has a bright prospect in China.

Key Topics Covered:

1 Relevant Concepts of Pregabalin

2 Sales of Pregabalin in China, 2013-2017

3 Major Pregabalin Manufacturers in China, 2013-2017

4 Prices of Pregabalin in China, 2017-2018

5 Prospects of Chinese Pregabalin Market, 2018-2022

Companies Mentioned

  • Chongqing Succeway Pharmaceutical Co., Ltd.
  • Pfizer

For more information about this report visit

View Comments and Join the Discussion!